# Sirius XM Holdings Inc.: financial statements, quarterly

SIRI · Nasdaq · CIK 908937 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/siri.md) · [Financials](/companies/siri/financials.md) · [Filings](/companies/siri/filings.md) · [Insiders](/companies/siri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/siri/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,271](/filings/0000908937-24-000028.md) | [2,288 d](/filings/0000908937-26-000006.md) | [2,162](/filings/0000908937-25-000010.md) | [2,178](/filings/0000908937-25-000023.md) | [2,171](/filings/0000908937-25-000030.md) | [2,188 d](/filings/0000908937-26-000006.md) | [2,068](/filings/0000908937-26-000011.md) | [2,138](/filings/0000908937-26-000022.md) | [2,159](/filings/0000908937-25-000030.md) | [2,193 d](/filings/0000908937-26-000006.md) | [2,091](/filings/0000908937-26-000011.md) | [2,160](/filings/0000908937-26-000022.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [1,227](/filings/0000908937-24-000028.md) | [1,235 d](/filings/0000908937-26-000006.md) | [1,136](/filings/0000908937-25-000010.md) | [1,166](/filings/0000908937-25-000023.md) | [1,156](/filings/0000908937-25-000030.md) | [1,159 d](/filings/0000908937-26-000006.md) | [1,076](/filings/0000908937-26-000011.md) | [1,120](/filings/0000908937-26-000022.md) | [1,128](/filings/0000908937-25-000030.md) | [1,163 d](/filings/0000908937-26-000006.md) | [1,105](/filings/0000908937-26-000011.md) | [1,144](/filings/0000908937-26-000022.md) |
| Research and development | $m | [72.0](/filings/0000908937-24-000028.md) | [88.0 d](/filings/0000908937-26-000006.md) | [86.0](/filings/0000908937-25-000010.md) | [71.0](/filings/0000908937-25-000023.md) | [68.0](/filings/0000908937-25-000030.md) | [72.0 d](/filings/0000908937-26-000006.md) | [73.0](/filings/0000908937-26-000011.md) | [56.0](/filings/0000908937-26-000022.md) | [62.0](/filings/0000908937-25-000030.md) | [72.0 d](/filings/0000908937-26-000006.md) | [69.0](/filings/0000908937-26-000011.md) | [56.0](/filings/0000908937-26-000022.md) |
| Operating income | $m | [528](/filings/0000908937-24-000028.md) | [455 d](/filings/0000908937-26-000006.md) | [409](/filings/0000908937-25-000010.md) | [471](/filings/0000908937-25-000023.md) | [(2,901)](/filings/0000908937-25-000030.md) | [505 d](/filings/0000908937-26-000006.md) | [387](/filings/0000908937-26-000011.md) | [365](/filings/0000908937-26-000022.md) | [493](/filings/0000908937-25-000030.md) | [226 d](/filings/0000908937-26-000006.md) | [454](/filings/0000908937-26-000011.md) | [472](/filings/0000908937-26-000022.md) |
| Interest expense | $m | [106](/filings/0000908937-23-000027.md) | [104 d](/filings/0000908937-24-000008.md) | [104](/filings/0000908937-24-000014.md) | [102](/filings/0000908937-24-000021.md) | [124](/filings/0000908937-25-000030.md) | [117 d](/filings/0000908937-26-000006.md) | [117](/filings/0000908937-26-000011.md) | [116](/filings/0000908937-26-000022.md) | [115](/filings/0000908937-25-000030.md) | [111 d](/filings/0000908937-26-000006.md) | [112](/filings/0000908937-26-000011.md) | [112](/filings/0000908937-26-000022.md) |
| Income tax | $m | [79.0](/filings/0000908937-24-000028.md) | [23.0 d](/filings/0000908937-26-000006.md) | [68.0](/filings/0000908937-25-000010.md) | [76.0](/filings/0000908937-25-000023.md) | [(39.0)](/filings/0000908937-25-000030.md) | [107 d](/filings/0000908937-26-000006.md) | [65.0](/filings/0000908937-26-000011.md) | [59.0](/filings/0000908937-26-000022.md) | [91.0](/filings/0000908937-25-000030.md) | [36.0 d](/filings/0000908937-26-000006.md) | [81.0](/filings/0000908937-26-000011.md) | [73.0](/filings/0000908937-26-000022.md) |
| Net income | $m | [234](/filings/0000908937-24-000028.md) | [172 d](/filings/0000908937-26-000006.md) | [199](/filings/0000908937-25-000010.md) | [304](/filings/0000908937-25-000023.md) | [(2,456)](/filings/0000908937-25-000030.md) | [287 d](/filings/0000908937-26-000006.md) | [204](/filings/0000908937-26-000011.md) | [205](/filings/0000908937-26-000022.md) | [297](/filings/0000908937-25-000030.md) | [99.0 d](/filings/0000908937-26-000006.md) | [245](/filings/0000908937-26-000011.md) | [239](/filings/0000908937-26-000022.md) |
| Diluted EPS | $ per share | [0.82](/filings/0000908937-24-000028.md) | not reported | [0.63](/filings/0000908937-25-000010.md) | [0.74](/filings/0000908937-25-000023.md) | [(8.74)](/filings/0000908937-25-000030.md) | not reported | [0.59](/filings/0000908937-26-000011.md) | [0.57](/filings/0000908937-26-000022.md) | [0.84](/filings/0000908937-25-000030.md) | not reported | [0.72](/filings/0000908937-26-000011.md) | [0.70](/filings/0000908937-26-000022.md) |
| Basic EPS | $ per share | [0.86](/filings/0000908937-24-000028.md) | not reported | [0.72](/filings/0000908937-25-000010.md) | [1.05](/filings/0000908937-25-000023.md) | [(8.74)](/filings/0000908937-25-000030.md) | not reported | [0.60](/filings/0000908937-26-000011.md) | [0.61](/filings/0000908937-26-000022.md) | [0.88](/filings/0000908937-25-000030.md) | not reported | [0.73](/filings/0000908937-26-000011.md) | [0.71](/filings/0000908937-26-000022.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0000908937-24-000028.md) | [0.3](/filings/0000908937-26-000006.md) | [0.1](/filings/0000908937-25-000010.md) | [0.2](/filings/0000908937-25-000023.md) | [0.1](/filings/0000908937-25-000030.md) | [0.2](/filings/0000908937-26-000006.md) | [0.1](/filings/0000908937-26-000011.md) | [0.1](/filings/0000908937-26-000022.md) | [0.1](/filings/0000908937-25-000030.md) | [0.1](/filings/0000908937-26-000022.md) | [0.1](/filings/0000908937-26-000011.md) | [0.2](/filings/0000908937-26-000022.md) |
| Current assets | $bn | [1.0](/filings/0000908937-23-000027.md) | [1.4](/filings/0000908937-25-000005.md) | [1.1](/filings/0000908937-24-000014.md) | [1.1](/filings/0000908937-24-000021.md) | [1.1](/filings/0000908937-24-000028.md) | [1.1](/filings/0000908937-26-000006.md) | [1.0](/filings/0000908937-25-000010.md) | [1.0](/filings/0000908937-25-000023.md) | [1.1](/filings/0000908937-25-000030.md) | [1.1](/filings/0000908937-26-000022.md) | [1.1](/filings/0000908937-26-000011.md) | [1.2](/filings/0000908937-26-000022.md) |
| Total assets | $bn | [10.1](/filings/0000908937-23-000027.md) | [30.1](/filings/0000908937-25-000005.md) | [11.2](/filings/0000908937-24-000014.md) | [11.2](/filings/0000908937-24-000021.md) | [27.5](/filings/0000908937-24-000028.md) | [27.5](/filings/0000908937-26-000006.md) | [27.4](/filings/0000908937-25-000010.md) | [27.3](/filings/0000908937-25-000023.md) | [27.4](/filings/0000908937-25-000030.md) | [27.2](/filings/0000908937-26-000022.md) | [27.1](/filings/0000908937-26-000011.md) | [27.2](/filings/0000908937-26-000022.md) |
| Current liabilities | $bn | [3.2](/filings/0000908937-23-000027.md) | [4.0](/filings/0000908937-25-000005.md) | [3.1](/filings/0000908937-24-000014.md) | [2.6](/filings/0000908937-24-000021.md) | [3.1](/filings/0000908937-24-000028.md) | [2.7](/filings/0000908937-26-000006.md) | [2.5](/filings/0000908937-25-000010.md) | [2.6](/filings/0000908937-25-000023.md) | [3.5](/filings/0000908937-25-000030.md) | [3.7](/filings/0000908937-26-000022.md) | [2.4](/filings/0000908937-26-000011.md) | [2.5](/filings/0000908937-26-000022.md) |
| Total liabilities | $bn | [13.0](/filings/0000908937-23-000027.md) | [17.0](/filings/0000908937-25-000005.md) | [13.5](/filings/0000908937-24-000014.md) | [13.3](/filings/0000908937-24-000021.md) | [16.6](/filings/0000908937-24-000028.md) | [16.4](/filings/0000908937-26-000006.md) | [16.2](/filings/0000908937-25-000010.md) | [16.0](/filings/0000908937-25-000023.md) | [15.8](/filings/0000908937-25-000030.md) | [15.7](/filings/0000908937-26-000022.md) | [15.4](/filings/0000908937-26-000011.md) | [15.3](/filings/0000908937-26-000022.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [(2.9)](/filings/0000908937-23-000027.md) | [10.1](/filings/0000908937-25-000005.md) | [(2.4)](/filings/0000908937-24-000021.md) | [(2.1)](/filings/0000908937-24-000021.md) | [10.9](/filings/0000908937-24-000028.md) | [11.1](/filings/0000908937-26-000022.md) | [11.2](/filings/0000908937-26-000022.md) | [11.3](/filings/0000908937-26-000022.md) | [11.6](/filings/0000908937-25-000030.md) | [11.6](/filings/0000908937-26-000022.md) | [11.7](/filings/0000908937-26-000022.md) | [11.9](/filings/0000908937-26-000022.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [500 d](/filings/0000908937-24-000028.md) | [528 d](/filings/0000908937-26-000006.md) | [264](/filings/0000908937-25-000010.md) | [489 d](/filings/0000908937-25-000023.md) | [309 d](/filings/0000908937-25-000030.md) | [679 d](/filings/0000908937-26-000006.md) | [242](/filings/0000908937-26-000011.md) | [546 d](/filings/0000908937-26-000022.md) | [430 d](/filings/0000908937-25-000030.md) | [680 d](/filings/0000908937-26-000006.md) | [271](/filings/0000908937-26-000011.md) | [722 d](/filings/0000908937-26-000022.md) |
| Capital expenditure | $m | [188 d](/filings/0000908937-24-000028.md) | [129 d](/filings/0000908937-26-000006.md) | [174](/filings/0000908937-25-000010.md) | [173 d](/filings/0000908937-25-000023.md) | [216 d](/filings/0000908937-25-000030.md) | [165 d](/filings/0000908937-26-000006.md) | [189](/filings/0000908937-26-000011.md) | [145 d](/filings/0000908937-26-000022.md) | [175 d](/filings/0000908937-25-000030.md) | [144 d](/filings/0000908937-26-000006.md) | [105](/filings/0000908937-26-000011.md) | [130 d](/filings/0000908937-26-000022.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [75.0 d](/filings/0000908937-24-000028.md) | [0.0 d](/filings/0000908937-26-000006.md) | [0.0](/filings/0000908937-25-000010.md) | [0.0 d](/filings/0000908937-25-000023.md) | [0.0 d](/filings/0000908937-25-000030.md) | [6.0 d](/filings/0000908937-26-000006.md) | [25.0](/filings/0000908937-26-000011.md) | [45.0 d](/filings/0000908937-26-000022.md) | [21.0 d](/filings/0000908937-25-000030.md) | [45.0 d](/filings/0000908937-26-000006.md) | [22.0](/filings/0000908937-26-000011.md) | [6.0 d](/filings/0000908937-26-000022.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3,968](/filings/0000908937-23-000027.md) | [3,939](/filings/0000908937-24-000014.md) | [3,873](/filings/0000908937-24-000021.md) | [360](/filings/0000908937-24-000028.md) | [373](/filings/0000908937-25-000010.md) | [378](/filings/0000908937-25-000023.md) | [339](/filings/0000908937-25-000030.md) | [357](/filings/0000908937-26-000011.md) | [357](/filings/0000908937-26-000022.md) | [356](/filings/0000908937-25-000030.md) | [338](/filings/0000908937-26-000011.md) | [342](/filings/0000908937-26-000022.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 337,066,891 at 2026-07-28, from the cover of the [10-Q filed 2026-07-30](/filings/0000908937-26-000022.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.